Cargando…

Effects of vancomycin‐induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects

Metformin is a major treatment for type 2 diabetes. This study was conducted to investigate the impact of gut microbiome dysbiosis on the pharmacokinetics and antihyperglycemic effects of metformin. Healthy adult males aged 19–45 years with no defecation abnormalities were recruited for this 4‐perio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Eunwoo, Kim, Andrew Hyoungjin, Lee, Yujin, Ji, Sang Chun, Cho, Joo‐Youn, Yu, Kyung‐Sang, Chung, Jae‐Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504811/ https://www.ncbi.nlm.nih.gov/pubmed/33982376 http://dx.doi.org/10.1111/cts.13051

Ejemplares similares

Assessment of Oral Vancomycin-Induced Alterations in Gut Bacterial Microbiota and Metabolome of Healthy Men
por: Kim, Andrew HyoungJin, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects
por: Jin, Xuanyou, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
por: Hwang, Inyoung, et al.
Publicado: (2020)

A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects
por: Kim, Eunwoo, et al.
Publicado: (2019)

Impact of Vancomycin‐Induced Changes in the Intestinal Microbiota on the Pharmacokinetics of Simvastatin
por: Sunwoo, Jung, et al.
Publicado: (2020)

620. Pharmacokinetic-Pharmacodynamic Analysis of Oral Vancomycin and Gut Microbiome Changes in Healthy Volunteers: an Exploratory Study
por: Jo, Jinhee, et al.
Publicado: (2022)

A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study
por: Chung, Hyewon, et al.
Publicado: (2018)

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
por: Park, Sang-In, et al.
Publicado: (2015)

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
por: Kim, Chang Hee, et al.
Publicado: (2017)

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
por: Hong, Taegon, et al.
Publicado: (2015)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

Association of metformin administration with gut microbiome dysbiosis in healthy volunteers
por: Elbere, Ilze, et al.
Publicado: (2018)

The Effects of Moxifloxacin on QTc Interval in Healthy Korean Male Subjects
por: Moon, Seol Ju, et al.
Publicado: (2014)

Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
por: Bi, Youwei, et al.
Publicado: (2018)

Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
por: Yoon, Seonghae, et al.
Publicado: (2015)

Gut microbiome differences between metformin‐ and liraglutide‐treated T2DM subjects
por: Wang, Zhang, et al.
Publicado: (2017)

Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects
por: Kim, Yun, et al.
Publicado: (2019)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon(®) and Eprex(®) following a single subcutaneous administration in healthy male volunteers
por: Yoon, Sumin, et al.
Publicado: (2017)

Alteration of Gut Immunity and Microbiome in Mixed Granulocytic Asthma
por: Gu, Bon-Hee, et al.
Publicado: (2022)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP(®)) Biosimilar, to Those of NESP(®) After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
por: Jeon, Inseung, et al.
Publicado: (2021)

A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects
por: Jung, Jin Ah, et al.
Publicado: (2015)

Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
por: Hwang, Sejung, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects
por: Park, Min Young, et al.
Publicado: (2023)

Population pharmacodynamics of cilostazol in healthy Korean subjects
por: Jung, Yun Seob, et al.
Publicado: (2018)

Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
por: Gu, Namyi, et al.
Publicado: (2014)

Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects
por: Park, Hyeonsoo, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects
por: Tsukamoto, Naohiro, et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects
por: Shibata, Mai, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects
por: Son, Yu-Jeong, et al.
Publicado: (2023)

Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin
por: Ruczyński, Jarosław, et al.
Publicado: (2019)

Effect of Vancomycin on the Gut Microbiome and Plasma Concentrations of Gut-Derived Uremic Solutes
por: Nazzal, Lama, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
por: Kim, Choon Ok, et al.
Publicado: (2016)

Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability
por: Tsunoda, Shirley M., et al.
Publicado: (2021)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

A Vancomycin HPLC Assay for Use in Gut Microbiome Research
por: Hu, Chenlin, et al.
Publicado: (2022)

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ekvlncsp7m01gvo4h7ndas95tt